Medicago Announces Phase 3 Study of VLP Quadrivalent Influenza Vaccine
Québec City (ots/PRNewswire) - The first plant-based seasonal flu vaccine candidate reaches final clinical stage Medicago, a Canadian biopharmaceutical company and leader in the development and production of plant-based vaccines and therapeutics, is proud to announce the start of a Phase 3 efficacy study for its seasonal quadrivalent influenza vaccine (QIV) candidate. ...
mehr